BioVie Inc. (BIVI) Prices 1.96M Share Offering at $1.53/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall St futures slip as tech losses mount ahead of key inflation data
- Oil prices rise after Trump says Iran must pay price
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Has Tesla solved the self-driving puzzle? This analyst thinks so
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
BioVie Inc. Announces Pricing of Public Offering
September 23, 2024 10:26 PM EDTCARSON CITY, Nev., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (BioVie or the Company), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of a best efforts public offering of 1,960,800 shares of its common stock (or pre-funded warrants (Pre-funded Warrants) in lieu thereof) and warrants to purchase up to 1,960,800 shares of common stock at a combined offering price of $1.53 per share (or Pre-funded Warrant) and associated warrant. The warrants will have an exercise price of $1.53 per share and will... More
